Sengenics Ramps Up for Further Growth, Announces Expansion of its Sales and Business Development Teams in the USA, Europe and Asia
Expansion key step in enhancing team's capabilities for providing direct commercial and technical support to collaborators and customers
SINGAPORE, Nov. 29, 2019 /PRNewswire-PRWeb/ -- Sengenics, the functional proteomics company, today announced the expansion of its global sales and business development teams, providing enhanced direct commercial and technical support to its collaborators and customers. The addition of new highly experienced regional hires and the development of strategic international alliances are key steps that Sengenics has taken to further enhance its team's capabilities in the USA, Europe and Asia.
Speaking on future plans for the company, Johan Poole-Johnson, Chief Commercial Officer, Sengenics, stated, "It has been an exciting 18 months for us. We are currently in collaboration with 8 of the world's top pharmaceutical companies on accelerating their drug decision-making process through utilisation of our KREX technology. We believe that the USA and Asia are key markets for the long-term, and we are particularly excited about playing a role in enabling precision medicine to improve patient outcomes. We will be expanding the applications of our KREX technology in the area of Companion Diagnostics, specifically on patient enrichment in clinical trials for cancer and autoimmune drugs. Our model is based on establishing collaborative partnerships for early stage opportunities in order to identify and develop innovative products which address mass market needs."
About Sengenics
Sengenics is a functional proteomics company that leverages its patented KREX technology for production of full-length, correctly folded and functional proteins. KREX was invented and patented by Professor Jonathan Blackburn whilst he was a member of the faculty at the University of Cambridge.
The key application of KREX is the discovery of autoantibody biomarkers for two core medical use cases. Firstly, stratification of patients undergoing treatment with autoimmune or cancer drugs into responders, non-responders and those that may exhibit severe immune-related adverse events (irAEs). Secondly, identification of autoantibody biomarkers that may be used to diagnose cancer, autoimmune or neurodegenerative conditions years before conventional diagnostic tests. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.
SOURCE Sengenics
Share this article